India Eyes Pharma PLI Overhaul to Boost Domestic API Production

India's government is reportedly planning a significant revamp of its Production Linked Incentive (PLI) scheme for bulk drugs, according to Pharmaceuticals Secretary Manoj Joshi. The initiative aims to reduce the nation's reliance on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), which currently expose India's pharmaceutical supply chain to considerable geopolitical and logistical risks. The current PLI scheme, launched in March 2020 with an outlay of ₹6,940 crore (approximately $830 million USD), sought to promote domestic manufacturing of 53 critical bulk drugs. However, progress has been slower than anticipated in certain categories, highlighting the need for recalibration. The proposed revamp will likely involve adjustments to incentive structures, eligibility criteria, and target drug categories to enhance effectiveness and accelerate the indigenization of API production. This strategic shift is driven by a recognition of the vulnerabilities inherent in global pharmaceutical supply chains, exacerbated by recent disruptions and geopolitical tensions. By fostering a more robust domestic API manufacturing base, India aims to bolster its drug security, reduce import bills, and strengthen its position as a global pharmaceutical manufacturing hub. Enhanced domestic production is also expected to create job opportunities and attract further investment into the pharmaceutical sector, contributing to broader economic growth. The successful implementation of a revised PLI scheme could significantly de-risk India's pharmaceutical industry, making it more resilient to external shocks. It could also improve cost efficiencies in the long run by reducing dependence on volatile international markets for raw materials. The government's focus on these 'critical classes of drugs' underscores a broader national security imperative alongside economic development goals.